Synaptogenix to Present Alzheimer’s Disease Data at World Congress of Neuroscience

Synaptogenix, Inc. (Nasdaq: SNPX) will present an abstract featuring secondary endpoint data of its Phase 2 Bryostatin-1 trial at the 11th International Brain Research Organization (IBRO) World Congress of Neuroscience to be held in September 2023 in Spain.

Dr. Alan Tuchman, Chief Executive Officer of Synaptogenix, said, “We believe that our Phase 2 trial Severe Cohort results provide evidence that Bryostatin-1 can prevent—not only slow—cognitive decline in advanced AD patients.”

Highlights

Synaptogenix’s Phase 2 clinical trial of Bryostatin-1 studied two cohorts, a Moderate Cohort and a Severe Cohort.

Moderate Cohort patients showed no significant benefit, while patients of the Severe Cohort, representing the patient population with the most advanced Alzheimer’s disease, achieved nearly all pre-specified secondary endpoints with statistical significance.

Recently approved Alzheimer’s drugs, such as lecanemab, aduhelm, and donanenemab, focus on early-stage dementia and mild cognitive impairment while Synaptogenix is working in a more severe disease cohort and have developed data that it believes indicates that severe Alzheimer’s deterioration can be prevented.

Synaptogenix’s Phase 2 study is sponsored by the National Institutes of Health (NIH)

As of March 31, 2023, Synaptogenix maintains a clean capital structure and strong cash position of $35.8 million.

About SynaptogeniSynaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer’s disease. Preclinical studies have also demonstrated bryostatin’s regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs. Additional information about Synaptogenix, Inc. may be found on its website: www.synaptogen.com.

Share This Article

 

About the Author

Synaptogenix to Present Alzheimer’s Disease Data at World Congress of Neuroscience

Editor Prism MarketView